Zhangxiang Zhao

Zhangxiang Zhao

Auto-generated profile, based on publicly available information

Zhangxiang Zhao

The Sino-Russian Medical Research Center of Jinan University, the Institute of Chronic Disease of Jinan University, the First Affiliated Hospital of Jinan University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2021 in Oncogene
Verified
Journal Article
Open access
PDF file
ZZZhangxiang Zhao
Zhangxiang Zhao
YGYingYing Guo
YingYing Guo
YLYaoyao Liu
Yaoyao Liu
LSLichun Sun
Lichun Sun
BCBo Chen
Bo Chen
XLXia Li
Xia Li
Long non-coding RNAs (lncRNAs) play key regulatory roles in breast cancer. However, population-level differential expression analysis methods disregard the heterogeneous expression of lncRNAs in individual patients. Therefore, we individualized lncRNA expression profiles for breast invasive carcinoma (BRCA) using the method of LncRNA Individualization (LncRIndiv). After evaluating the robustness ofLncRIndiv, we constructed an individualized differentially expressed lncRNA (IDElncRNA) profile for BRCA and investigated the subtype-specific IDElncRNAs. The breast cancer subtype-specific IDElncRNA showed frequent co-occurrence with alterations of protein-coding genes, including mutations, copy number variation and differential methylation. We performed hierarchical clustering to subdivide TNBC and revealed mesenchymal subtype and immune subtype for TNBC. The TNBC immune subtype showed a better prognosis than the TNBC mesenchymal subtype. LncRNAPTOV1-AS1was the top differentially expressed lncRNA in the mesenchymal subtype. And biological experiments validated that the upregulation ofPTOV1-AS1could downregulateTJP1(ZO-1) and E-Cadherin, and upregulate Vimentin, which suggestsPTOV1-AS1may promote epithelial-mesenchymal transition and lead to migration and invasion of TNBC cells. The mesenchymal subtype showed a higher fraction of M2 macrophages, whereas the immune subtype was more associated with CD4 + T cells. The immune subtype is characterized by genomic instability and upregulation of immune checkpoint genes, thereby suggesting a potential response to immunosuppressive drugs. Last, drug response analysis revealed lncRNA ENSG00000230082 (PRRT3-AS1) is a potential resistance biomarker for paclitaxel in BRCA treatment. Our analysis highlights that IDElncRNAs can characterize inter-tumor heterogeneity in BRCA and the new TNBC subtypes indicate novel insights into TNBC immunotherapy.

26 May 2022 in British Journal of Cancer
Verified
Journal Article
Closed access
PDF file
TCTingting Chen
Tingting Chen
TYTong Yu
Tong Yu
SZShuping Zhuang
Shuping Zhuang
YGYiding Geng
Yiding Geng
JXJunwen Xue
Junwen Xue
YGYunyan Gu
Yunyan Gu

20 October 2021 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
SZShuping Zhuang
Shuping Zhuang
TCTingting Chen
Tingting Chen
YLYawei Li
Yawei Li
YWYuquan Wang
Yuquan Wang
LALiqiang Ai
Liqiang Ai
YGYunyan Gu
Yunyan Gu
Pancreatic cancer (PC) with homologous recombination deficiency (HRD) has been reported to benefit from poly ADP-ribose polymerase (PARP) inhibitors. However, accurate identification of HRD status for PC patients from the transcriptional level is still a great challenge. Here, based on a relative expression ordering (REO)-based algorithm, we developed an HRD signature including 24 gene pairs (24-GPS) using PC transcriptional profiles from The Cancer Genome Atlas (TCGA). HRD samples classified by 24-GPS showed worse overall survival (p = 4.4E-3 for TCGA; p = 1.2E-3 for International Cancer Genome Consortium-Australia cohort; p = 6.4E-2 for GSE17891; p = 7.5E-2 for GSE57495) and higher HRD scores than non-HRD samples (p = 1.4E-4). HRD samples showed highly unstable genomic characteristics and also displayed HRD-related alterations at the epigenomic and proteomic levels. Moreover, HRD cell lines identified by 24-GPS tended to be sensitive to PARP inhibitors (p = 6.6E-2 for olaparib; p = 2.6E-3 for niraparib). Compared with the non-HRD group, the HRD group presented lower immune scores and CD4/CD8 T cell infiltration proportion. Interestingly, PC tumor cells with co-inhibition of PARP-related genes and ATR showed reduced survival ability. In conclusion, 24-GPS can robustly identify PC patients with HRD status at the individualized level.

24 August 2023 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
MLMingyue Liu
Mingyue Liu
QDQi Dong
Qi Dong
BCBo Chen
Bo Chen
KLKaidong Liu
Kaidong Liu
ZZZhangxiang Zhao
Zhangxiang Zhao
YGYunyan Gu
Yunyan Gu
Background: Immune checkpoint inhibitors (ICI) have revolutionized the treatment for multiple cancers. However, most of patients encounter resistance. Synthetic viability (SV) between genes could induce resistance. In this study, we established SV signature to predict the efficacy of ICI treatment for melanoma. Methods: We collected features and predicted SV gene pairs by random forest classifier. This work prioritized SV gene pairs based on CRISPR/Cas9 screens. SV gene pairs signature were constructed to predict the response to ICI for melanoma patients. Results: This study predicted robust SV gene pairs based on 14 features. Filtered by CRISPR/Cas9 screens, we identified 1,861 SV gene pairs, which were also related with prognosis across multiple cancer types. Next, we constructed the six SV pairs signature to predict resistance to ICI for melanoma patients. This study applied the six SV pairs signature to divide melanoma patients into high-risk and low-risk. High-risk melanoma patients were associated with worse response after ICI treatment. Immune landscape analysis revealed that high-risk melanoma patients had lower natural killer cells and CD8+ T cells infiltration. Conclusions: In summary, the 14 features classifier accurately predicted robust SV gene pairs for cancer. The six SV pairs signature could predict resistance to ICI.

8 July 2020 in Aging
Verified
Journal Article
Open access
TCTingting Chen
Tingting Chen
ZZZhangxiang Zhao
Zhangxiang Zhao
BCBo Chen
Bo Chen
YWYuquan Wang
Yuquan Wang
FYFan Yang
Fan Yang
YGYunyan Gu
Yunyan Gu
The epithelial-mesenchymal transition (EMT) process is involved in cancer cell metastasis and immune system activation. Hence, identification of gene expression signatures capable of predicting the EMT status of cancer cells is essential for development of therapeutic strategies. However, quantitative identification of EMT markers is limited by batch effects, the platform used, or normalization methods. We hypothesized that a set of EMT-related relative expression orderings are highly stable in epithelial samples yet are reversed in mesenchymal samples. To test this hypothesis, we analyzed transcriptome data for ovarian cancer cohorts from publicly available databases, to develop a qualitative 16-gene pair signature (16-GPS) that effectively distinguishes the mesenchymal from epithelial phenotype. Our method was superior to previous quantitative methods in terms of classification accuracy and applicability to individualized patients without requiring data normalization. Patients with mesenchymal-like ovarian cancer showed poorer overall survival compared to patients with epithelial-like ovarian cancer. Additionally, EMT score was positively correlated with expression of immune checkpoint genes and metastasis. We, therefore, established a robust EMT 16-GPS that is independent of detection platform, batch effects and individual variations, and which represents a qualitative signature for investigating the EMT and providing insights into immunotherapy for ovarian cancer patients.